Floatz logo

Erythromycin

Levodopa

Virginia Commonwealth UniversitySmall moleculeN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Levodopa cohort.

Same molecule, other indications

Erythromycin is also rated in:

classic familial adenomatous polyposisDormant
BB
Indicative ·
65 / 100
View asset →
colorectal cancerDormant
B
Indicative ·
57 / 100
View asset →
non-small cell lung carcinomaDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →